Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Colors Of The Fall

This article was originally published in Scrip

Executive Summary

Something strange is happening in the stock market. What ended up as the best week of the year for the broad S&P 500 index was a down-week and month to date for the NASDAQ Biotechnology Index (NBI). This is not supposed to happen since the biotech sector is higher beta, meaning that if the broad equity index finishes the week up, the NBI should finish the week up more.

You may also be interested in...



Stockwatch: Pricing Delusions Of Blockbuster Proportions

Sales expectations for the products of companies like Acadia, BTG, Keryx and probably Sarepta remain too high, despite the bursting of the last biotech bubble. Aggressive price increases have traditionally been one way to inch closer to those expectations but that door has closed.

Stockwatch: Reading The Tea Leaves For Pharma Q1 Earnings

Contrasting first-quarter preannouncements from a DNA sequencing company and a molecular diagnostics company may, with other seasonal pressures, imply a comparatively weak first quarter for therapeutic drug companies.

Stockwatch: The Two Sides Of A Complete Response Letter

The FDA’s rejection of Acadia’s label expansion into a broader patient population for its only approved drug resulted in an aggrieved reaction. Better disclosure from both sides would have helped.

Topics

Related Companies

UsernamePublicRestriction

Register

SC030026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel